Compremium Quantis CVP
Precision without Penetration
Why it exists
The Compremium Quantis CVP was created to close a long-standing gap in venous pressure assessment, preserving physiological relevance while removing the barriers that historically limited access to this insight.
It reflects Compremium’s commitment to advancing quantitative, non-invasive physiological assessment in a responsible and clinically grounded way.
What it is
The Compremium Quantis CVP is a non-invasive solution designed to enable quantified venous pressure assessment (QVPA) using ultrasound-guided measurement principles.
By combining peripheral vein visualisation with controlled external pressure, the Compremium Quantis CVP enables objective assessment of venous collapse pressure, providing a quantitative surrogate for central venous pressure without catheter insertion.
What defines it
The Compremium Quantis CVP is built around three core principles:
1. Physiological relevance
Designed to reflect venous pressure meaningfully, not indirectly.
2. Non-invasive by design
Eliminates the need for central venous access while maintaining clinical utility.
3. Quantitative and reproducible
Focused on objective measurement that can be tracked over time and across settings.
How it fits into care
The Compremium Quantis CVP is designed to support clinical decision-making, not replace it.
It provides objective context to help clinicians:
- assess venous pressure and congestion earlier
- understand when escalation is warranted
- integrate venous physiology into broader patient assessment
The Breakthrough
The Compremium Quantis CVP has received FDA Breakthrough Device Designation and has been accepted into the FDA Total Product Life Cycle Advisory Program (TAP).
These programmes are designed to support earlier, more frequent, and more strategic engagement with the FDA to help expedite patient access to important device innovations.
Designed for the future
The Compremium Quantis CVP is currently in development as part of Compremium’s broader innovation roadmap.
It represents a step toward a future where venous pressure can be assessed meaningfully, earlier, and across the continuum of care, without forcing clinicians to choose between insight and safety.
This is the next evolution in venous pressure assessment.
Swiss engineered
2026 Compremium AG
Follow us on LinkedIn